A Circulating Subpopulation of Monocytic Myeloid-Derived Suppressor Cells as an Independent Prognostic/Predictive Factor in Untreated Non-Small Lung Cancer Patients
Table 4
Univariate and multivariate analysis for PFS and median OS for NSCLC patients.
(a) Univariate analysis
Hazard ratio (95% CI)
value
PFS
Age (≥70 vs <70)
1.628 (0.958–2.765)
0.072
Gender (male vs female)
1.817 (0.723–4.566)
0.204
Histology (Non-Adeno vs Adeno)
1.075 (0.632–1.828)
0.789
Stage (IV vs IIIA/IIIB)
2.150 (1.078–4.288)
0.030
CD14+CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
2.343 (1.331–4.124)
0.02
CD14+CD11b+CD33+CD15−HLA-DR−Lin− (above vs below 90% of controls)
1.076 (0.458–2.526)
0.866
CD14−CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
1.115 (0.603–2.063)
0.729
OS
Age (≥70 vs <70)
1.516 (0.849–2.708)
0.160
Gender (male vs female)
2.553 (0.792–8.233)
0.117
Histology (Non-Adeno vs Adeno)
1.006 (0.562–1.800)
0.984
Stage (IV vs IIIA/IIIB)
2.060 (0.947–4.481)
0.068
CD14+CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
2.349 (1.252–4.407)
0.008
CD14+CD11b+CD33+CD15−HLA-DR−Lin− (above vs below 90% of controls)
1.697 (0.521–5.527)
0.344
CD14−CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
1.071 (0.556–2.063)
0.836
(b) Multivariate analysis
Hazard ratio (95% CI)
value
PFS
Stage (IV vs IIIA/IIIB)
1.838 (0.918–3.680)
0.086
CD14+CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
2.408 (1.368–4.241)
0.002
OS
CD14+CD11b+CD33+CD15+HLA-DR−Lin− (above vs below 90% of controls)
